Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce it has signed a partnership with City Dock Pharmacy in London, to launch a walk-in pain clinic offering specialised medicines, including medicinal cannabis, which is the first of its kind.
The pain clinic, which will be based at City Dock Pharmacy in Wapping, London, will offer both appointment-based and walk-in services. The clinic will leverage Kanabo’s Treat It online platform, and pharmacists will be on hand to guide patients through the medicinal cannabis treatment options. Furthermore, the clinic supports the delivery of personalised treatment plans for the growing number of chronic pain sufferers in the UK, who often face difficulties accessing medical treatments due to long waiting times, bureaucracy and affordability.
The partnership with City Dock Pharmacy will combine Kanabo’s expertise in medicinal cannabis with traditional treatments for pain management and will cater for patients who are eligible for alternative therapies, as traditional treatments have not delivered improvements. The partnership with City Dock Pharmacy should result in an increase of patients who receive treatment through Kanabo’s Treat It platform.
The launch of the walk-in pain clinic with City Dock Pharmacy represents progress against the Group’s strategy, as announced on 29 September 2023, to extend its reach into physical pharmacies across the UK offering Kanabo’s services to patients. The Company will seek to replicate this model across more pharmacies, leveraging the extensive pharmacy network partnership in Kanabo’s digital health division.
Avihu Tamir, Chief Executive Officer of Kanabo, commented:
“This collaboration is a testament to our dedication to innovating in pain management. The combination of City Dock Pharmacy’s trusted presence and our expertise in medicinal cannabis paves the way for a new, holistic approach to treating pain and the opportunity to extend this to additional indications.”
